 |
 |
 |
 |
 |
 |
 |
|
Beta-Gly
Glycoferon is our proprietary long-acting type I interferon for the treatment of multiple sclerosis. Standard-of-care in this indication consists of non-glycosylated interferon-b. By applying our glycosylation technology, we intend to develop a novel therapy with a more convenient, once weekly administration profile while remaining unaltered with respect to efficacy profile. |